Of note, polymorphisms in PNPLA3 and TM6SF might be “master regulators” of metabolic syndrome outcomes, which potentially determine the full range of NAFLD manifestations from hepatic fat accumulation to liver cancer [15]. Here, PNPLA3 is linked to metabolic syndrome.